1-2 of 2
Mohammad Azab, MD, MSC, MBA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS)

Kiyomi Morita, MDPhD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Kristy R. Bodden, Feng Wang, PhD, Prithviraj Bose, MD, Yesid Alvarado, MD, Naval Daver, MD, Gautam Borthakur, MD, Farhad Ravandi, MBBS, Koichi Takahashi, MD PhD, Elias Jabbour, MD, Courtney D. DiNardo, MD MSCE, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Maro Ohanian, DO, Sherry A. Pierce, BSN, BA, Mohammad Azab, MD MSc, MBA, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-140614
Published: 2020
Journal Articles

SGI-110, a Novel Second Generation Potent DNA Methylation Inhibitor, In Development for the Treatment of MDS and AML. Preclinical Safety, Pharmacokinetics, and DNA Methylation Results of a Low Volume Subcutaneous (SC) Formulation

Jason Scholl, PhD, Rajashree Joshi-Hangal, PhD, Roger Inloes, PhD, Chongtie Shi, PhD, Pietro Taverna, PhD, Gavin S. Choy, PharmD, MBA, Sanjeev Redkar, PhD, Mohammad Azab, MD, MSC, MBA
Journal: Blood
Blood (2010) 116 (21): 1872.
https://doi.org/10.1182/blood.V116.21.1872.1872
Published: 2010